Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway

Nouf M. Al-Rasheed, Maha M. Al-Oteibi, Reem Z. Al-Manee, Sarah A. Al-Shareef, Nawal M. Al-Rasheed, Iman H. Hasan, Raeesa A. Mohamad, Ayman M. Mahmoud

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

Simvastatin (SIM) is a lipid-soluble inhibitor of hydroxy-3-methylglutaryl coenzyme A reductase with multiple reported therapeutic benefits. The present study was designed to investigate the effect of pretreatment with SIM on isoproterenol (ISO)-induced cardiac hypertrophy in rats. Twenty-four male albino Wistar rats weighing 180–200 g were divided into four groups. Groups I and III received normal saline while groups II and IV received SIM (10 mg/kg body weight) for 30 days per gavage. In the last 7 days, rats of groups III and IV were administered ISO (5 mg/kg) intraperitoneally to induce cardiac hypertrophy. Administration of ISO induced an increase in heart-to-body weight (HW/BW) ratio, an increase in serum interleukin-6, and elevated systolic and diastolic blood pressure. Serum levels of lipids, cardiovascular risk indices, and cardiac troponin I and creatine phosphokinase-MB showed significant increase in ISO-induced hypertrophic rats. Histopathological examination of heart tissue revealed focal areas of subendocardium degeneration, mononuclear cellular infiltrations, fibrous tissue deposition, and increased thickness of the myocardium of left ventricle. In addition, ISO-administered rats exhibited significant upregulation of cardiac Janus kinase, phosphorylated signal transducer and activator of transcription, and nuclear factor-kappa B. Pretreatment with SIM significantly prevented ISO-induced cardiac hypertrophy, alleviated the altered biochemical parameters, and improved the heart architecture. In conclusion, our study provides evidence that SIM prevented the development of cardiac hypertrophy via modulation of the Janus kinase/signal transducer and activator of transcription-signaling pathway in the heart of ISO-administered animals.

Original languageEnglish
Pages (from-to)3217-3229
Number of pages13
JournalDrug Design, Development and Therapy
Volume9
DOIs
Publication statusPublished - 23 Jun 2015

Fingerprint

Simvastatin
Cardiomegaly
Isoproterenol
Janus Kinases
Transducers
Body Weight
Blood Pressure
Lipids
Troponin I
NF-kappa B
Coenzyme A
Creatine Kinase
Serum
Heart Ventricles
Wistar Rats
Interleukin-6
Myocardium
Oxidoreductases
Transcription Factors
Up-Regulation

Keywords

  • Cardiac hypertrophy
  • IL-6
  • Isoproterenol
  • JAK/STAT pathway
  • Simvastatin

Cite this

Al-Rasheed, N. M., Al-Oteibi, M. M., Al-Manee, R. Z., Al-Shareef, S. A., Al-Rasheed, N. M., Hasan, I. H., ... Mahmoud, A. M. (2015). Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. Drug Design, Development and Therapy, 9, 3217-3229. https://doi.org/10.2147/DDDT.S86431
Al-Rasheed, Nouf M. ; Al-Oteibi, Maha M. ; Al-Manee, Reem Z. ; Al-Shareef, Sarah A. ; Al-Rasheed, Nawal M. ; Hasan, Iman H. ; Mohamad, Raeesa A. ; Mahmoud, Ayman M. / Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. In: Drug Design, Development and Therapy. 2015 ; Vol. 9. pp. 3217-3229.
@article{c8dace2520814b718bee8cbea0f6456b,
title = "Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway",
abstract = "Simvastatin (SIM) is a lipid-soluble inhibitor of hydroxy-3-methylglutaryl coenzyme A reductase with multiple reported therapeutic benefits. The present study was designed to investigate the effect of pretreatment with SIM on isoproterenol (ISO)-induced cardiac hypertrophy in rats. Twenty-four male albino Wistar rats weighing 180–200 g were divided into four groups. Groups I and III received normal saline while groups II and IV received SIM (10 mg/kg body weight) for 30 days per gavage. In the last 7 days, rats of groups III and IV were administered ISO (5 mg/kg) intraperitoneally to induce cardiac hypertrophy. Administration of ISO induced an increase in heart-to-body weight (HW/BW) ratio, an increase in serum interleukin-6, and elevated systolic and diastolic blood pressure. Serum levels of lipids, cardiovascular risk indices, and cardiac troponin I and creatine phosphokinase-MB showed significant increase in ISO-induced hypertrophic rats. Histopathological examination of heart tissue revealed focal areas of subendocardium degeneration, mononuclear cellular infiltrations, fibrous tissue deposition, and increased thickness of the myocardium of left ventricle. In addition, ISO-administered rats exhibited significant upregulation of cardiac Janus kinase, phosphorylated signal transducer and activator of transcription, and nuclear factor-kappa B. Pretreatment with SIM significantly prevented ISO-induced cardiac hypertrophy, alleviated the altered biochemical parameters, and improved the heart architecture. In conclusion, our study provides evidence that SIM prevented the development of cardiac hypertrophy via modulation of the Janus kinase/signal transducer and activator of transcription-signaling pathway in the heart of ISO-administered animals.",
keywords = "Cardiac hypertrophy, IL-6, Isoproterenol, JAK/STAT pathway, Simvastatin",
author = "Al-Rasheed, {Nouf M.} and Al-Oteibi, {Maha M.} and Al-Manee, {Reem Z.} and Al-Shareef, {Sarah A.} and Al-Rasheed, {Nawal M.} and Hasan, {Iman H.} and Mohamad, {Raeesa A.} and Mahmoud, {Ayman M.}",
year = "2015",
month = "6",
day = "23",
doi = "10.2147/DDDT.S86431",
language = "English",
volume = "9",
pages = "3217--3229",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

Al-Rasheed, NM, Al-Oteibi, MM, Al-Manee, RZ, Al-Shareef, SA, Al-Rasheed, NM, Hasan, IH, Mohamad, RA & Mahmoud, AM 2015, 'Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway', Drug Design, Development and Therapy, vol. 9, pp. 3217-3229. https://doi.org/10.2147/DDDT.S86431

Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. / Al-Rasheed, Nouf M.; Al-Oteibi, Maha M.; Al-Manee, Reem Z.; Al-Shareef, Sarah A.; Al-Rasheed, Nawal M.; Hasan, Iman H.; Mohamad, Raeesa A.; Mahmoud, Ayman M.

In: Drug Design, Development and Therapy, Vol. 9, 23.06.2015, p. 3217-3229.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway

AU - Al-Rasheed, Nouf M.

AU - Al-Oteibi, Maha M.

AU - Al-Manee, Reem Z.

AU - Al-Shareef, Sarah A.

AU - Al-Rasheed, Nawal M.

AU - Hasan, Iman H.

AU - Mohamad, Raeesa A.

AU - Mahmoud, Ayman M.

PY - 2015/6/23

Y1 - 2015/6/23

N2 - Simvastatin (SIM) is a lipid-soluble inhibitor of hydroxy-3-methylglutaryl coenzyme A reductase with multiple reported therapeutic benefits. The present study was designed to investigate the effect of pretreatment with SIM on isoproterenol (ISO)-induced cardiac hypertrophy in rats. Twenty-four male albino Wistar rats weighing 180–200 g were divided into four groups. Groups I and III received normal saline while groups II and IV received SIM (10 mg/kg body weight) for 30 days per gavage. In the last 7 days, rats of groups III and IV were administered ISO (5 mg/kg) intraperitoneally to induce cardiac hypertrophy. Administration of ISO induced an increase in heart-to-body weight (HW/BW) ratio, an increase in serum interleukin-6, and elevated systolic and diastolic blood pressure. Serum levels of lipids, cardiovascular risk indices, and cardiac troponin I and creatine phosphokinase-MB showed significant increase in ISO-induced hypertrophic rats. Histopathological examination of heart tissue revealed focal areas of subendocardium degeneration, mononuclear cellular infiltrations, fibrous tissue deposition, and increased thickness of the myocardium of left ventricle. In addition, ISO-administered rats exhibited significant upregulation of cardiac Janus kinase, phosphorylated signal transducer and activator of transcription, and nuclear factor-kappa B. Pretreatment with SIM significantly prevented ISO-induced cardiac hypertrophy, alleviated the altered biochemical parameters, and improved the heart architecture. In conclusion, our study provides evidence that SIM prevented the development of cardiac hypertrophy via modulation of the Janus kinase/signal transducer and activator of transcription-signaling pathway in the heart of ISO-administered animals.

AB - Simvastatin (SIM) is a lipid-soluble inhibitor of hydroxy-3-methylglutaryl coenzyme A reductase with multiple reported therapeutic benefits. The present study was designed to investigate the effect of pretreatment with SIM on isoproterenol (ISO)-induced cardiac hypertrophy in rats. Twenty-four male albino Wistar rats weighing 180–200 g were divided into four groups. Groups I and III received normal saline while groups II and IV received SIM (10 mg/kg body weight) for 30 days per gavage. In the last 7 days, rats of groups III and IV were administered ISO (5 mg/kg) intraperitoneally to induce cardiac hypertrophy. Administration of ISO induced an increase in heart-to-body weight (HW/BW) ratio, an increase in serum interleukin-6, and elevated systolic and diastolic blood pressure. Serum levels of lipids, cardiovascular risk indices, and cardiac troponin I and creatine phosphokinase-MB showed significant increase in ISO-induced hypertrophic rats. Histopathological examination of heart tissue revealed focal areas of subendocardium degeneration, mononuclear cellular infiltrations, fibrous tissue deposition, and increased thickness of the myocardium of left ventricle. In addition, ISO-administered rats exhibited significant upregulation of cardiac Janus kinase, phosphorylated signal transducer and activator of transcription, and nuclear factor-kappa B. Pretreatment with SIM significantly prevented ISO-induced cardiac hypertrophy, alleviated the altered biochemical parameters, and improved the heart architecture. In conclusion, our study provides evidence that SIM prevented the development of cardiac hypertrophy via modulation of the Janus kinase/signal transducer and activator of transcription-signaling pathway in the heart of ISO-administered animals.

KW - Cardiac hypertrophy

KW - IL-6

KW - Isoproterenol

KW - JAK/STAT pathway

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=84933055813&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S86431

DO - 10.2147/DDDT.S86431

M3 - Article

VL - 9

SP - 3217

EP - 3229

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -